Beijing Boren Hospital is the lead sponsor of 8 current clinical trials in our China register. 6 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are AFN50 and Car-T. The most-studied condition is Autoimmune Disease.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
NCT07361094 · ClinicalTrials.gov ↗ · Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis, Relapsed/Refractory Idiopathic Inflammatory Myopathies
|
Phase 1 | Recruiting | 2025-11 | China |
|
A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases
NCT07448298 · ClinicalTrials.gov ↗ · Relapsed/Refractory Autoimmune Diseases
Drug: AFN50 |
Phase EARLY_PHASE1 | Recruiting | 2026-03 | China |
|
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
NCT07626476 · ClinicalTrials.gov ↗ · Relapsed/Refractory Light Chain Amyloidosis, AL Amyloidosis, Systemic Light Chain Amyloidosis
|
Phase EARLY_PHASE1 | Recruiting | 2024-12 | China |
|
Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis
NCT06983951 · ClinicalTrials.gov ↗ · Light Chain Amyloidosis
|
Not applicable | Recruiting | 2025-02 | China |
|
Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
NCT06993493 · ClinicalTrials.gov ↗ · Autoimmune Disease
|
Not applicable | Recruiting | 2025-02 | China |
|
Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
NCT06983964 · ClinicalTrials.gov ↗ · Autoimmune Disease
|
Not applicable | Recruiting | 2025-02 | China |
|
A Study of CAR-T Cells Targeting Autoimmune Diseases
NCT06661811 · ClinicalTrials.gov ↗ · Autoimmune Diseases
Drug: Car-T |
Not applicable | Not yet open | 2024-11 | China |
|
A Study of BEN301 Injection in the Treatment of Autoimmune Diseases
NCT07502859 · ClinicalTrials.gov ↗ · SSC RA SS IIM
|
Phase EARLY_PHASE1 | Not yet open | 2026-03 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 8 | 6 |
A trial with sites in more than one country appears in each of those registers.
Beijing Boren Hospital is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 2 drugs and biologicals as interventions. The most frequent are AFN50 (1) and Car-T (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.